BioNTech Results Presentation Deck

BNT311: Phase 1 / 2a - Dose Escalation Patient Demographics Dose Escalation Cohort Median age, years (range) Age group, n (%) <65 years ≥65 years Female, n (%) Cancer type, a n (%) Colorectal cancer Ovarian cancer Pancreatic cancer NSCLC Other Median number of prior regimens, (range) Prior treatment with PD-(L)1 inhibitor, n (%) 16 All patients N=61 59 (23, 79) 44 (72.1) 17 (27.9) 28 (45.9) 12 (19.7) 9 (14.8) 6 (9.8) 6 (9.8) 28 (45.9) 3 (1-11) 23 (37.7) ● ● A total of 61 patients were enrolled in the dose escalation part of the trial Patients were heavily pretreated, receiving a median (range) of 3 (1-11) treatments; nearly 40% had received prior PD-(L)1 treatment BIONTECH

View entire presentation